Fresh analysis reveals that individuals who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who end conventional diet and exercise regimens.
Published data in a prominent medical journal points out that while overweight people can lose a large proportion of their body weight while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month after stopping.
"People using such drugs need to be informed of the danger of rapid rebound weight gain when the medication ends," cautioned expert Dr. Susan Jebb.
Such speed of recovery means a return to pre-treatment mass in about a year and a half.
Comparing Treatments
The analysis, which reviewed dozens of studies involving over 9,000 of patients, compared the results of the injectable medications with other pills.
The team point out that people who lose weight through dieting typically see a less rapid creep back—approximately 0.1 kg a month—once they finish.
Explaining the Rapid Regain
Nutrition scientists propose the mechanism of the injections is key to understanding the amplified regain.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which controls hunger.
"Long-term administration of GLP-1 levels far above than normal could lead to the body to produce less of its own natural GLP-1, and could lessen sensitivity to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication means hunger is no longer kept in check, making binge eating much more probable."
An Ongoing Issue?
Medical guidelines suggest the jabs for individuals with weight-linked health risks, alongside recommended lifestyle changes.
Professionals say that, considering the high risk of weight regain, the treatment might need to be life-long.
This view is reinforced by drug manufacturers, who note that the results "underscore the persistent nature of excess weight," similar to managing conditions like high blood pressure.
User Experiences
Users who have stopped the jabs report a intense resurgence of appetite.
"I experienced a trigger flipping and you become ravenous," described one woman.
The struggle is worsened if individuals have not developed sustainable lifestyle or habit modifications during therapy.
Growing Use
Survey data suggest that millions of adults in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is greater among females than males.
- The 40s and 50s age group shows the highest usage rates.
- Many access the drugs through private prescriptions rather than the NHS.
In conclusion, clinicians caution that while these medications are powerful agents for weight loss, they are not a standalone fix and maintained weight loss likely depends on integrated behavioural changes.
